Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cold Spring Harbor Molecular Case Studies|September 15, 2016
A novel de novo mutation in ATP1A3 and childhood-onset schizophreniaNiklas Smedemark-Margulies, Catherine A Brownstein, Sigella Vargas, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 19, 2022
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disordersBeverly L Davidson, Guangping Gao, Elizabeth Berry-Kravis, et al.American Journal of Medical Genetics. Part A|February 19, 2016
Overlapping 16p13.11 deletion and gain of copies variations associated with childhood onset psychosis include genes with mechanistic implications for autism associated pathways: Two case reportsCatherine A Brownstein, Robin J Kleiman, Elizabeth C Engle, et al.Molecular Genetics and Metabolism Reports|June 21, 2018
<i>De novo ATP1A3</i> and compound heterozygous <i>NLRP3</i> mutations in a child with autism spectrum disorder, episodic fatigue and somnolence, and muckle-wells syndromeAlcy Torres, Catherine A Brownstein, Sahil K Tembulkar, et al.Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.The Journal of Pharmacology and Experimental Therapeutics|February 14, 2012
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivoRobin J Kleiman, Douglas S Chapin, Curt Christoffersen, et al.Journal of Medicinal Chemistry|June 3, 2017
Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A InhibitorChristopher J Helal, Eric P Arnold, Tracey L Boyden, et al.Journal of Medicinal Chemistry|January 3, 2018
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical CandidateChristopher J Helal, Eric Arnold, Tracey Boyden, et al.Pageof 3